7d agoInvestors.comBEARISH 34M&A
AstraZeneca Stock Nosedives On Rumored Mega-Merger With Bristol Myers Squibb
AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb.
Archived explainer. For the current picture see today's AZN page.
Why Is ASTRAZENECA PLC (AZN) Stock Down Today?
By the Top Tier Newswire AI Desk · August 3, 2026 at 10:10 AM ET · reviewed against 35 wire stories
ASTRAZENECA PLC (AZN) is down -7.65% in the latest session. Our newswire has captured 35 stories on AZN across 17 sources in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
AstraZeneca PLC shares fell 7.65% to $156.66 on Monday as reports surfaced that the pharmaceutical giant is reportedly in merger discussions with Bristol Myers Squibb. The potential $400 billion deal has sparked uncertainty among investors, leading to a sharp decline in AZN’s stock. The session opened with a 4.6% gap down from the previous close, and the stock continued to decline throughout the morning before stabilizing slightly in the final hours of trading.
What Happened
The rumored merger between AstraZeneca and Bristol Myers Squibb has raised questions about the strategic rationale and regulatory hurdles that such a massive deal might face. Analysts have called the potential combination "odd," noting the differing growth trajectories of the two companies. AstraZeneca has outperformed Bristol Myers Squibb in recent pharmaceutical growth metrics, while Bristol Myers has seen weaker performance. The stock’s sharp decline reflects investor skepticism and uncertainty over the merger’s feasibility and implications for both companies.
What The Data Shows
The intraday session showed a volatile start, with the stock opening at $161.85 and reaching a high of $162.75 before falling to a low of $155.27. The stock closed at $156.62, with a volume of 2.2 million shares, which is in line with the 3-month average. Over the past 8 sessions, the stock had shown minimal movement, rising just 0.2% from $170.12 to $170.41. Recent insider transactions include a sale of $2.2 million by Sharma Mani, while congressional trades show several small purchases by lawmakers. Retail traders on social media platforms have expressed mixed views, with some calling the stock oversold and others highlighting speculative call bets.
What To Watch
Investors will be watching for further developments in the rumored merger discussions, as well as any official statements from either company. No earnings report is scheduled in the near term, but coverage breadth remains high with 35 stories from 17 sources in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AZN by the numbers
Last: $156.66Session: -7.65%7 sessions: -6.36%Coverage: 35 stories / 17 sourcesAI sentiment: 50/100 (mixed)Mkt cap: $264.1BP/E: 25.452w: $72.89 to $212.71
The headlines behind the move
7d agoBloombergBULLISH 55M&A
AstraZeneca, Bristol-Myers: A $400 Billion Pharma Deal Could Get Really Messy
7d agoQuartzBULLISH 56M&A
AstraZeneca, Bristol Myers Squibb exploring merger talks - qz.com
A combination of the two pharmaceutical companies could create an entity valued at nearly $400 billion, according to the Financial Times
7d agoMorningstarNEUTRAL 52M&A
An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it 'odd'
AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
7d agoSeeking AlphaBULLISH 58M&A
AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks
AstraZeneca and Bristol Myers Squibb reportedly discuss a merger as AZN leads pharma growth rankings and BMY trails.
7d agoCNBCBULLISH 56M&A
AstraZeneca merging with Bristol Myers would be a big cost-cutting deal: Mizuho's Jared Holz
Jared Holz, Mizuho Securities healthcare sector specialist, joins 'Squawk Box' to discuss reports that AstraZeneca is in talks with Bristol Myers Squibb over a megadeal and more.
7d agoCNBCNEUTRAL 50General
Stocks making the biggest moves premarket: Alibaba, AstraZeneca, eBay & more
These are the stocks posting the largest moves premarket.
7d agoThe Motley FoolBULLISH 63M&A
Breakfast News: Pharma's $400B Blockbuster Brewing
BMY and AZN reportedly talk of a merger, stocks rebound as jobs print approaches, and more...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on AZN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AZN move explainers: 2026-08-04 · 2026-08-03 · 2026-07-27